Samrat Pharmachem Ltd Share Price

Samrat Pharma
Small Cap | Pharmaceuticals
₹ 285 -4.15 (-1.44%)
Last updated: 04-Nov-2025 , 16:01:37

Samrat Pharmachem Ltd Live Price Chart

Low: ₹285 High: 293.95
Open Your Trading & Demat Account
+91

Samrat Pharmachem Ltd Technicals

Current Price
₹ 285 -4.15 (-1.44%)
EMASMA
20 Day ₹ 295.585
50 Day ₹ 308.296
100 Day ₹ 324.340
200 Day ₹ 343.737
20 Day ₹ 295.773
50 Day ₹ 308.760
100 Day ₹ 329.422
200 Day ₹ 341.837

Samrat Pharmachem Ltd Performance

Previous Close ₹ 289.15
High ₹ 293.95
Volume 1041
52W Range ₹ 271.1 - ₹ 511
Open ₹ 290
Low ₹ 285
Market Cap 88.21 Cr

Samrat Pharmachem Ltd Fundamentals

ROCE 12.923
P/E Ratio 18.310
P/B Ratio 1.230
Industry P/E 1.230
Debt to Equity 41.050
ROE 9.906
EPS 15.590
Dividend Yield 0.350
Book Value 232.386
Face Value 10.000

Samrat Pharmachem Ltd Financials

Particulars Y202503 Y202403 Y202303 Y202203 Y202103
Total Revenue 286.8339 282.9658 311.1236 222.3846 179.4806
Total Expenses 276.9478 280.4456 288.5932 198.7837 172.1191
Profit After Tax 7.1122 2.1626 16.6305 17.1848 5.3332

Samrat Pharmachem Ltd Shareholding Pattern

Promoter Holdings 49.091 %
FIIs 3.237 %
DIIs 0.000 %
MutualFund 0.000 %
Retail 41.727 %
Others - 5.945 %

About Samrat Pharmachem Ltd

History of Samrat Pharmachem Ltd

Samrat Pharmachem Limited was incorporated on June 16, 1992 at Ankleshwar in Gujarat led by the Promoters, Mr. Lalit Mehta & Mr. Rajesh Mehta. Since then, it envisioned to focus on lodine Derivatives as their core products. The Company's principal activities are manufacturing and selling chemicals. Company is a producer of pharmaceutical chemicals. The intermediates produced are used in pharmaceutical and chemical industries. Your Company is amongst the manufacturers who produce for local and international needs of the pharmaceuticals and chemicals industry. The company has two plants producing varied items. The basic purpose of producing in two different plants is to improve efficiency and manageability. SPL started commercial production of Iodine Derivatives in April, 1993. In Octobe ...

Similar Stocks

Company 52 Week Market Price P/E Ratio
Gujarat Themis Biosyn Ltd ₹ 208 - ₹ 479 460 112.84
Jubilant Pharmova Ltd ₹ 802 - ₹ 1309.9 1178 1027.17
Anuh Pharma Ltd ₹ 74.25 - ₹ 122.85 87.41 19.06
Aarti Drugs Ltd ₹ 312 - ₹ 564.05 505 25.86
Aarey Drugs & Pharmaceuticals Ltd ₹ 31.35 - ₹ 98.17 98.16 66.78

FAQs on Samrat Pharmachem Ltd

1. Can I buy Samrat Pharmachem Ltd from PL Capital? ›

Yes, you can invest in Samrat Pharmachem Ltd shares directly through PL Capital. Our platform provides a seamless and secure way to buy, hold, and track Samrat Pharmachem Ltd stock along with other leading companies listed on the NSE and BSE. Simply open a Demat and trading account with PL Capital, and you’ll be able to trade Samrat Pharmachem Ltd as well as diversify your portfolio across equities, mutual funds, IPOs, and more.

2. Does Samrat Pharmachem Ltd pay dividends? ›

Yes, Samrat Pharmachem Ltd has a consistent history of rewarding its shareholders through dividend payouts. Dividend frequency and amounts vary depending on the company’s financial performance and board approvals. Investors holding Samrat Pharmachem Ltd shares on the record date announced by the company are eligible to receive dividends directly into their bank accounts linked with their Demat holdings.

3. What is the current share price of Samrat Pharmachem Ltd ? ›

As of 04-11-2025 the share price for Samrat Pharmachem Ltd. is 285.5 on the NSE (Note: Prices are dynamic and update frequently during market hours).

4. What is the 52-week high and low of Samrat Pharmachem Ltd ? ›

The 52-week high and low of Samrat Pharmachem Ltd share price is ₹ 271.1 - ₹ 511 as of 04-11-2025 .
PL Ringside View

Our fireside chat series where industry experts and top management share valuable insights for our clients

Youtube

Mark Mobius on India’s Growth, Global Markets, and Investment Opportunities

Youtube

₹100 cr net profit in 7-12 months | Anjali Nashier, Revolt Motors

Youtube

India's Path to Energy Security | Dr. Praveer Sinha, MD & CEO, Tata Power

  • PL Capital Logo

  • Regd. Office : 3rd Floor, Sadhana House,
    570, P. B. Marg, Behind Mahindra Tower,
    Worli, Mumbai - 400 018, India

    View on Google Maps

  • Tel. : 02266322222

    Call us

Prabhudas Lilladher Private Limited | CIN: U67190MH1983PTC029670 | Registered Office Address: 3rd Floor, Sadhana House, 570, P.B. Marg, Worli, Mumbai – 400018, Maharashtra, India | SEBI Registration Details: Stock Broking: INZ000196637 [Membership Codes: NSE – 05977; BSE – 564; MCX – 40690] | Depository Participant: IN-DP-439-2019 [DP Codes: CDSL – 12011300; NSDL – IN303868 | Portfolio Management: INP000009001| Research Analyst: INZ000000271 | Investment Advisors: INA000018267 [BSEASL Membership Code: BASL2042] | AMFI ARN: 3276 | Compliance Officer: Mrs. Snehal Kathrani; Tel: 02266322420; email: co@plindia.com | For any Grievance/ Dispute: Stock Broking; email: grievance-br@plindia.com; Tel: 02266322366; Depository Participant; email: grievance-dp@plindia.com; Tel: 02266322452; Portfolio Management; email: grievance-pms@plindia.com; Tel: 02266322350.

To register your grievance on SCORES log onto: https://scores.gov.in/scores/Welcome.html. Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, Email ID

To register your grievance on Smart ODR Portal log onto: Online Dispute Resolution Portal (ODR Portal).

Standard Disclaimers: (a) Investment in securities market are subject to market risks, read all the related documents carefully before investing. (b) Brokerage will not exceed the SEBI prescribed limits. (c) Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

The brand name and Logo ‘PL Capital’ are the registered trademarks of Prabhudas Lilladher Advisory Services Private Limited which is the holding company of Prabhudas Lilladher Group of Companies .

Prabhudas Lilladher Private Limited is not associated with any unregulated platform which claims performance/return for algorithmic strategy for trading. Trading with unregulated platforms for algorithmic strategy shall be at your own risk and Prabhudas Lilladher Private Limited or its affiliates shall not be liable for the same.

Risk Disclosure on Derivatives: (a) 9 out of 10 individual traders in equity futures and options segment, incurred net losses. (b) On an average, loss makers registered net trading loss close to ₹ 50,000 (c) Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs. (d) Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source